• E²-RADIatE - Illustration

    The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • News from the ESTRO 2021 congress: EORTC-ESTRO RADiation Infrastructure for Europe (E2-RADIatE) OligoCare trial assesses real-world patterns of practice of radical radiotherapy for oligometastatic disease

  • News from the ESTRO 2021 congress: Denis Lacombe, awarded honorary membership of ESTRO, emphasises the importance of radiation oncology in multidisciplinary research

  • Radiation oncology priorities for clinical trials

    Radiation oncology priorities for clinical trials

  • E2-RADIate

    PRESS RELEASE: EORTC and ESTRO announce E2-RADIatE platform’s first site activation for Oligometastatic Disease

  • Innovation For Value And Acces ESTRO37

    EORTC and ESTRO announce a new collaboration to maximise the benefits of radiation oncology

  • Innovation For Value And Acces ESTRO37

    EORTC at ESTRO37 Congress

  • Brain tumour

    Interim Results of the CATNON Study – the Effects of Temozolomide